DCAAA mitigates neuroinflammation and microglial pyroptosis in spinal cord injury by inhibiting PI3K/AKT/NF-κB and NLRP3/caspase-1/GSDMD signaling

Jun 9, 2025European journal of pharmacology

DCAAA reduces nerve inflammation and cell death in spinal cord injury by blocking specific inflammation and cell-damage pathways

AI simplified

Abstract

Treatment with DCAAA significantly reduced oxidative stress and improved motor function after spinal cord injury.

  • DCAAA suppressed the expression of pyroptosis-related proteins and pro-inflammatory cytokines following spinal cord injury.
  • Histological analyses indicated enhanced axonal regeneration and improved motor function with DCAAA treatment.
  • In vitro studies showed that DCAAA mitigated cell activation and oxidative stress in microglial cells.
  • DCAAA is associated with targeting specific molecular pathways that may reduce microglial pyroptosis.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free